ORYL Photonics closes its series A round in a record time

Tuesday, September 9, 2025 @ 12:00 am

ORYL Photonics announces the successful closing of its Series A round. The round was backed by existing shareholders. Their investment commitment has been achieved in record time of two weeks. This milestone marks a major step forward for the fast-growing Swiss company, which is pioneering advanced solutions for measuring the solubility and aggregation of drug molecules and biologics in the life science sector. The investment will further accelerate the rollout of its recently launched ORYL F1 platform instrument.

"We are thrilled to have successfully closed this funding round, which once again demonstrates the strong confidence our investors have in our vision," shares Orly Tarun, CEO & Co-founder of ORYL Photonics. "With our light-scattering technology, we are committed to rethink solubility and aggregation measurement and set new boundaries – empowering researchers in the pharmaceutical, chemical, and life sciences industries and accelerating their work."

A capital injection for commercialization and scaling up
ORYL Photonics completed its Series A round in July 2025. Founded by Orly Tarun and Nathan Dupertuis in 2020, the startup based in Epalinges launched in May 2025 the ORYL F1, a laboratory instrument based on an advanced form of laser-based light scattering technology. The spin-off from EPFL received over the last years more than CHF 4 million in non-dilutive funding, grants, and awards from various organizations such as Innosuisse, the European Innovation Council (EIC), the Fondation pour l’Innovation et la Technologie (FIT), the European Research Commission (ERC), and EPFL. The Series A funding will help ORYL Photonics to commercialize its laboratory instrument, to develop its ‘solubility measurement service’ offer, and to prepare for its scaling-up.

A technological breakthrough for life science R&D
Measuring how drugs dissolve or aggregate in liquids is crucial for the development of efficient therapeutics. ORYL Photonics closes the gap in solubility measurement with its platform instrument. Based on a proprietary laser-based light scattering technology and the ‘Solvent Redistribution method’ – born at EPFL – the ORYL F1 is the world’s-first solution that disrupts the way solubility and aggregation measurement is performed: with high efficiency (rapid throughput), accuracy, and requiring the least quantity of compounds. It provides a straightforward analysis and an automated testing process for pharmaceutical and biotechnological companies, while saving precious compounds compared to existing technologies.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

abc biopply, ZHAW, and UZH join for cancer immunotherapy testing

In a groundbreaking collaboration, abc biopply AG, the Zurich University of Applied Sciences (ZHAW), and the University of Zurich (UZH) have joined forces to develop a next-generation 3D multi-organoid in vitro platform designed to transform drug development and personalized cancer therapy. The initiative is supported by the Swiss national funding agency Innosuisse.
September 8, 2025

SOPHiA GENETICS and Jessa Ziekenhuis announce precision oncology partnership

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a significant new collaboration with Jessa Ziekenhuis in Hasselt, Belgium. The institutions will partner to bring cutting edge genomic testing and oncology research to cancer patients across Belgium.
September 5, 2025

Neurimmune's created AL-S Pharma announces positive results for the treatment of amyotrophic lateral sclerosis

In 2016, Neurimmune and TVM Capital Life Science co-created AL-S Pharma to develop AP-101. AL-S Pharma has executed its innovative clinical plan for AP-101 in collaboration with an international network of ALS experts. Phase 2 of AP-101 in sporadic ALS and mutant SOD1-ALS met its primary safety and tolerability endpoint Clinically meaningful changes in outcome measures and stabilization of biomark
September 4, 2025

Topadur Pharma strengthens board with professor Thierry Carrel

Topadur Pharma AG, a Swiss biopharmaceutical company developing innovative therapies for aging-related diseases, announces the appointment of Professor Thierry Carrel, MD, to its Board of Directors. Professor Carrel is one of Switzerland’s most accomplished cardiac surgeons. His expertise in clinical needs, regulatory navigation, and innovative technologies will provide strategic direction as To
August 12, 2025

Newron starts patient enrollment for Phase III trial on treatment-resistant schizophrenia

August 13, 2025